This form of ATH434 was used in the Company's Phase 2 clinical trials in MSA and will be utilized in the planned Phase 3 study. The patent extends protection for ATH434 to at least 2045, and together with existing intellectual property (IP) and regulatory designations, provides multi-layered market protection. "Overall, this patent enhances the strategic value of ATH434, supporting potential partnerships and other opportunities to advance development. Composition of matter claims are widely recognized as one of the strongest forms of pharmaceutical patent protection. About Multiple System AtrophyMultiple System Atrophy (MSA) is a rare, neurodegenerative disease characterized by failure of the autonomic nervous system and impaired movement.